Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1997 Feb 1;43(6):375–381. doi: 10.1007/s002620050347

Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma

T Takeuchi 1, Tetsuo Ueki 1, Yukihiro Sasaki 1, Takahiro Kajiwara 1, Baoxing Li 1, Nobuo Moriyama 1, Kazuki Kawabe 1
PMCID: PMC11037687  PMID: 9067410

Abstract

 Tumor regression in experimental systems has been linked to the activities of Th1 cells. It is, therefore, conceivable that Th2 cells interrupt the expression of tumor immunity since interleukin-4 (IL-4) and IL-10 inhibit the generation of Th1 from precursors and modulate the competence of antigen-presenting cells to activate this lymphocyte subpopulation. Naive murine renal cell carcinoma (renca) cells (1×105) were implanted into the subcapsule of the left kidney of Balb/c and Balb/c nude mice at 6 – 8 weeks of age. After 14 days, Th2 cytokine (IL-4 and IL-10) mRNAs as well as transforming growth factor β1 mRNA, assessed by reverse transcriptase/polymerase chain rea

ction were upregulated in the spleen of hosts upon naive renca tumor acceptance, while Th1 cytokine (IL-2 and interferon γ) mRNAs were almost undetectable. In the renca tumor, IL-10 mRNA was detected but IL-2, interferon γ, and IL-4 were not. Intraperitoneal administration of anti-(mouse IL-4) mAb (11B11) reduced the renca tumor size (

P = 0.018) and prolonged host survival (P = 0.03), but did not reduce the acceptance rate of the tumor (P = 0.18). However,

prior depletion of CD4+ or CD8+ cells with monoclonal antibodies abrogated the antitumor effects of anti-IL-4 mAb. In addition, the significant antitumor effect of anti-IL-4 mAb was not observed in Balb/c nude hosts. Renca cells we

re transfected with the mammalian expression vector pCAGGS containing murine IL-4 cDNA or vector alone, then stable IL-4 transfectants (RencaL or RencaH, low- or high-IL-4-producing respectively) and control renca cells (RencaC) were obtained. RencaL cell

s, RencaH cells, or RencaC cells (1×105 each) were implanted into the subcapsule of the left kidney of Balb/c, Balb/c nude, and allogenic C3H/HeJ mice, then tumor formation was evaluated 14 days later. When RencaH cells were innoculated into syngeneic Balb/c hosts, tumor volume was marginally

suppressed (P = 0.03) and tumors tended to be rejected (P = 0.06) compared with RencaC cells. However, those effects were not observed in Balb/c nude mice. RencaC, RencaL, and RencaH cells were not accepted by allogeneic C3H mice with or without FK506 administration or donor-specific trans

fusion. The administration of anti-(mouse IL-4) mAb to Balb/c mice significantly suppressed renca tumor growth by a CD4+ and CD8+ T-cell-dependent mechanism. By contrast, relatively high levels of IL-4 production by renca cells and T cells seemed to be required to induce the rejection and growth suppression of IL-4-producing renca cells in syngeneic hosts.

Keywords: Key words Th1, Th2, Cytokine, Anti-IL-4 mAb, Renca

Footnotes

Received: 9 September 1996 / Accepted: 3 December 1996


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES